We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

STRECK LABORATORIES

Develops and manufactures products for clinical and research laboratories in biotechnology, clinical controls, hemato... read more Featured Products: More products

Download Mobile App




Whole Cell Glycated Hemoglobin Control Calibrated for Most Popular Instruments

By LabMedica International staff writers
Posted on 22 Dec 2014
Laboratories that measure glycated hemoglobin (HbA1c) now have available a whole blood cell control material that has been calibrated for several major autoanalyzers.

HbA1c is a derivative of hemoglobin that is formed nonenzymically by reaction at the N terminus of the protein molecule with glucose. More...
In the normal adult human such derivatives constitute a few percent of the total erythrocyte hemoglobin, the most abundant being hemoglobin A1c, which increases several fold in concentration in diabetes mellitus, and is assayed to monitor control of diabetes. Once a hemoglobin molecule is glycated, it remains that way. A buildup of glycated hemoglobin within the red cell, therefore, reflects the average level of glucose to which the cell has been exposed during its life-cycle. Measuring glycated hemoglobin assesses the effectiveness of therapy by monitoring long-term serum glucose regulation. The HbA1c level is proportional to average blood glucose concentration over the previous four weeks to three months.

The American Diabetes Association and the World Health Organization have suggested that an HbA1c level of 6.5% or more is an indicator of type II diabetes and an HbA1c level of between 5.7 and 6.4% is an indicator of pre-diabetes.

Streck, Inc. (Omaha, NE, USA), an industry leader in the development and manufacturing of products for clinical and research laboratories, has released its A1c-Cellular control product, the only HbA1c control on the market with intact red blood cells.

The A1c-Cellular control is convenient to use, as it does not require reconstitution. It controls the entire HbA1c assay procedure, including the lysing of the red blood cells—a step omitted with other controls. This important feature ensures the entire system—instrument and reagents—is working properly and providing accurate patient results.

The A1c-Cellular control has been calibrated and certified for use on many of the major clinical autoanalyzers including: the Abbott (North Chicago, IL, USA) ARCHITECT c Systems; the Beckman Coulter (Indianapolis, IN, USA) UniCel DxC 600/800; the Bio-Rad (Hercules, CA, USA) D-10/Variant II and Variant II Turbo; the Roche (Pleasanton, CA, USA) cobas INTEGRA/6000/c311; the Siemens (Malvern, PA, USA) Dimension Series; and the Tosoh (Grove City, OH, USA) A1c analyzer, HLC-723G7.

A1c-Cellular control is available in two clinically significant levels: 4%–7% HbA1c (Level 1) and 9%–13% HbA1c (Level 2).

Related Links:

Streck, Inc. 



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.